
May 22 (Reuters) - Quoin Pharmaceuticals Ltd 2EB0y.F:
QUOIN PHARMACEUTICALS ANNOUNCES FDA CLEARANCE TO INITIATE SECOND PIVOTAL WHOLE BODY QRX003 NETHERTON SYNDROME CLINICAL STUDY
QUOIN PHARMACEUTICALS LTD - EXPECTS TO COMPLETE RECRUITMENT BY Q1 2026 AND FILE NDA LATER IN YEAR
Further company coverage: [2EB0y.F]